Xencor (NASDAQ:XNCR) Trading Up 7.9% – Should You Buy?

Xencor, Inc. (NASDAQ:XNCR) rose 7.9% during mid-day trading on Friday . The stock traded as high as $15.97 and last traded at $16.1360. Approximately 127,126 shares were traded during mid-day trading, a decline of 84% from the average session volume of 796,496 shares. The stock had previously closed at $14.95.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on XNCR shares. Wall Street Zen downgraded shares of Xencor from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. Truist Financial reduced their price target on shares of Xencor from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a research note on Wednesday, June 24th. Zacks Research upgraded shares of Xencor from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Finally, JPMorgan Chase & Co. lifted their price target on Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research report on Monday, May 11th. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.25.

Xencor Price Performance

The company has a market cap of $1.20 billion, a P/E ratio of -7.06 and a beta of 0.86. The company’s 50-day moving average is $13.12 and its two-hundred day moving average is $12.76.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.96). Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The business had revenue of $4.52 million during the quarter, compared to the consensus estimate of $27.86 million. During the same quarter in the previous year, the business posted ($0.66) earnings per share. Xencor’s quarterly revenue was down 86.2% compared to the same quarter last year. Equities research analysts anticipate that Xencor, Inc. will post -3.88 EPS for the current year.

Institutional Investors Weigh In On Xencor

Hedge funds and other institutional investors have recently modified their holdings of the stock. BVF Inc. IL raised its stake in shares of Xencor by 160.3% in the fourth quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock worth $109,217,000 after buying an additional 4,393,579 shares during the period. Legal & General Group Plc grew its stake in Xencor by 603.7% during the third quarter. Legal & General Group Plc now owns 1,273,000 shares of the biopharmaceutical company’s stock valued at $14,932,000 after acquiring an additional 1,092,095 shares in the last quarter. State Street Corp increased its holdings in shares of Xencor by 22.7% in the fourth quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock worth $69,006,000 after purchasing an additional 833,423 shares during the last quarter. Jefferies Financial Group Inc. boosted its position in shares of Xencor by 620.4% during the 4th quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock valued at $11,030,000 after acquiring an additional 620,440 shares during the last quarter. Finally, RTW Investments LP grew its stake in shares of Xencor by 8.9% in the 4th quarter. RTW Investments LP now owns 6,777,461 shares of the biopharmaceutical company’s stock worth $103,763,000 after buying an additional 556,407 shares in the last quarter.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.